Publication: A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia
Issued Date
2018-12-01
Resource Type
ISSN
14683083
09269959
09269959
Other identifier(s)
2-s2.0-85050452082
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the European Academy of Dermatology and Venereology. Vol.32, No.12 (2018), 2257-2263
Suggested Citation
P. Suchonwanit, P. Srisuwanwattana, N. Chalermroj, S. Khunkhet A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology. Vol.32, No.12 (2018), 2257-2263. doi:10.1111/jdv.15171 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46143
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia
Other Contributor(s)
Abstract
© 2018 European Academy of Dermatology and Venereology Background: The synergism of combined use between oral finasteride and topical minoxidil has been established in treating androgenetic alopecia among men. However, the concern regarding adverse effects of finasteride use has been rising. Objective: To compare the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in men with androgenetic alopecia. Methods: Forty men aged 18–60 years with androgenetic alopecia were randomized to 24 weeks of treatment with a finasteride/minoxidil or minoxidil solution twice daily. Primary efficacy endpoint was the change from baseline in hair density and hair diameter at week 24. Secondary endpoints included global photographic assessment by treatment-blinded investigators and subjects. Changes in plasma dihydrotestosterone levels and adverse events were recorded. Results: At week 24, the combined solution of finasteride and minoxidil was significantly superior to minoxidil alone in improvements of hair density, hair diameter and global photographic assessment (all P < 0.05). About 90% of patients treated with the combined solution experienced moderate to marked improvement. The combined solution also had minimal effect on plasma dihydrotestosterone levels, approximately 5% reduction. There were also no systemic adverse events reported by patients in both groups. Conclusion: Treatment with topical solution of 0.25% finasteride admixed with 3% minoxidil was significantly superior to 3% minoxidil solution for promoting hair growth in male androgenetic alopecia, and well tolerated.